Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY, Frison L, Halperin JL, Lane DA. Lip GY, et al. Among authors: halperin jl. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024. Epub 2010 Nov 24. J Am Coll Cardiol. 2011. PMID: 21111555 Free article. Clinical Trial.
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB. Huisman MV, et al. Among authors: halperin jl. Am Heart J. 2014 Mar;167(3):329-34. doi: 10.1016/j.ahj.2013.12.006. Epub 2013 Dec 19. Am Heart J. 2014. PMID: 24576516
Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY; GLORIA-AF Investigators. Huisman MV, et al. Among authors: halperin jl. Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073. Epub 2016 Jun 21. Europace. 2016. PMID: 27335063 Free PMC article.
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.
Paquette M, Riou França L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV, Lip GYH, Nieuwlaat R. Paquette M, et al. Among authors: halperin jl. J Am Coll Cardiol. 2017 Sep 26;70(13):1573-1583. doi: 10.1016/j.jacc.2017.07.793. J Am Coll Cardiol. 2017. PMID: 28935034 Free article.
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH; GLORIA-AF Investigators. Mazurek M, et al. Among authors: halperin jl. Thromb Haemost. 2017 Dec;117(12):2376-2388. doi: 10.1160/TH17-08-0555. Epub 2017 Dec 6. Thromb Haemost. 2017. PMID: 29212125 Free PMC article.
458 results